TY - JOUR
T1 - The vaginal and gastrointestinal microbiomes in gynecologic cancers
T2 - A review of applications in etiology, symptoms and treatment
AU - Chase, Dana
AU - Goulder, Alison
AU - Zenhausern, Frederic
AU - Monk, Bradley
AU - Herbst-Kralovetz, Melissa
N1 - Funding Information:
The authors would like to thank Mr. Sean Winkle for graphical assistance and Ms. Daniele Sumner for her editorial and administrative support. In addition, we apologize to all of those whose papers could not be cited due to scope and space limitations. This work was supported in part by the Flinn Foundation (grant no. 1974 ) (DMC and MMH-K).
Publisher Copyright:
© 2015 Elsevier Inc.
PY - 2015/7/1
Y1 - 2015/7/1
N2 - The human microbiome is the collection of microorganisms in the body that exist in a mutualistic relationship with the host. Recent studies indicate that perturbations in the microbiome may be implicated in a number of diseases, including cancer. More specifically, changes in the gut and vaginal microbiomes may be associated with a variety of gynecologic cancers, including cervical cancer, uterine cancer, and ovarian cancer. Current research and gaps in knowledge regarding the association between the gut and vaginal microbiomes and the development, progression, and treatment of gynecologic cancers are reviewed here. In addition, the potential use of probiotics to manage symptoms of these gynecologic cancers is discussed. A better understanding of how the microbiome composition is altered at these sites and its interaction with the host may aid in prevention, optimization of current therapies, development of new therapeutic agents and/or dosing regimens, and possibly limit the side effects associated with cancer treatment.
AB - The human microbiome is the collection of microorganisms in the body that exist in a mutualistic relationship with the host. Recent studies indicate that perturbations in the microbiome may be implicated in a number of diseases, including cancer. More specifically, changes in the gut and vaginal microbiomes may be associated with a variety of gynecologic cancers, including cervical cancer, uterine cancer, and ovarian cancer. Current research and gaps in knowledge regarding the association between the gut and vaginal microbiomes and the development, progression, and treatment of gynecologic cancers are reviewed here. In addition, the potential use of probiotics to manage symptoms of these gynecologic cancers is discussed. A better understanding of how the microbiome composition is altered at these sites and its interaction with the host may aid in prevention, optimization of current therapies, development of new therapeutic agents and/or dosing regimens, and possibly limit the side effects associated with cancer treatment.
KW - Bacterial therapeutics
KW - Commensal microbiota
KW - Dysbiosis
KW - Epithelial barrier function
KW - Probiotics
KW - Quality of life
KW - Radiation and chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=84931568592&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84931568592&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2015.04.036
DO - 10.1016/j.ygyno.2015.04.036
M3 - Review article
C2 - 25957158
AN - SCOPUS:84931568592
VL - 138
SP - 190
EP - 200
JO - Gynecologic Oncology
JF - Gynecologic Oncology
SN - 0090-8258
IS - 1
ER -